Zynerba Pharmaceuticals Inc. (ZYNE)

8.47
NASDAQ : Health Technology
Prev Close 8.01
Day Low/High 8.03 / 8.93
52 Wk Low/High 5.59 / 15.13
Avg Volume 583.90K
Exchange NASDAQ
Shares Outstanding 17.62M
Market Cap 141.17M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Interesting ZYNE Put And Call Options For November 16th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

My Buy-Write Strategy Amid Market Swings

My Buy-Write Strategy Amid Market Swings

It's a simple option strategy to mitigate some risk in deploying new funds.

Zynerba Pharmaceuticals Reaches Analyst Target Price

Zynerba Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zynerba Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $13.00, changing hands for $13.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Short Interest In Zynerba Pharmaceuticals Moves 27.4% Higher

Short Interest In Zynerba Pharmaceuticals Moves 27.4% Higher

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 609,213 share increase in total short interest for Zynerba Pharmaceuticals Inc , to 2,836,313, an increase of 27.35% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Zynerba Pharmaceuticals Reaches Analyst Target Price

Zynerba Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zynerba Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $8.14, changing hands for $9.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Notable Thursday Option Activity: ZYNE, EPC, RDI

Notable Thursday Option Activity: ZYNE, EPC, RDI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zynerba Pharmaceuticals Inc , where a total of 12,054 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 361.3% of ZYNE's average daily trading volume over the past month of 333,605 shares.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Zynerba Pharmaceuticals Announces That Results From Phase 2 STOP Trial Support Continued Development Of ZYN002 In Osteoarthritis

Zynerba Pharmaceuticals Announces That Results From Phase 2 STOP Trial Support Continued Development Of ZYN002 In Osteoarthritis

Zynerba to host conference call and webcast today, August 14 at 8:30 am ET

Zynerba Pharmaceuticals Announces Top-Line Results From Phase 2 STAR 1 Trial Of ZYN002 In Adult Epilepsy Patients With Focal Seizures

Zynerba Pharmaceuticals Announces Top-Line Results From Phase 2 STAR 1 Trial Of ZYN002 In Adult Epilepsy Patients With Focal Seizures

Company to host conference call and webcast today, August 7 at 8:30am ET

Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results And Operational Highlights

Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results And Operational Highlights

Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017

Notable Thursday Option Activity: ZYNE, SF, UTHR

Notable Thursday Option Activity: ZYNE, SF, UTHR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zynerba Pharmaceuticals Inc , where a total of 2,909 contracts have traded so far, representing approximately 290,900 underlying shares. That amounts to about 59.9% of ZYNE's average daily trading volume over the past month of 485,830 shares.